If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
The Latest on: Precision cancer medicine
via Google News
The Latest on: Precision cancer medicine
- Genetron Health Releases 22 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2021on April 12, 2021 at 10:31 pm
Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology ... enable the accurate diagnosis and treatment of cancer, facilitating the design of ...
- Combination of drugs promising for brain tumor treatmenton April 12, 2021 at 11:38 am
Glioblastoma is a type of cancer that can form in the brain or spinal cord. The drugs used in the clinical trial are atezolizumab, an immunotherapy drug, and ipatasertib, a new precision drug ...
- Evolving World of Biomarker Testing and Therapeutic Strategies: Realizing the Promise of Personalized Medicineon April 12, 2021 at 11:10 am
For the future of precision medicine, many health care providers ... medical oncologist at Florida Cancer Specialists and assistant professor of Internal Medicine, University of Central Florida Cancer ...
- Cancer DNA blood tests validated by international research teamon April 12, 2021 at 8:00 am
An international team today reports the findings of an independent assessment of five commercially-available assays for tumor DNA sequencing—a fast, cheap and less invasive method to diagnose and ...
- Cancer DNA Blood Tests Validated – Fast, Cheap and Less Invasive Method to Diagnose and Monitor Canceron April 12, 2021 at 8:00 am
An international team today reports the findings of an independent assessment of five commercially-available assays for tumor DNA sequencing - a fast, cheap and less invasive method to diagnose and ...
- New genetic drug target for treatment resistant colorectal canceron April 12, 2021 at 5:08 am
Targeting a specific cancer survival gene in colorectal cancer could lead to new treatment options for advanced disease, new research suggests.
- Measuring ctDNA With ddPCR May Help Drive Precision Medicine in Pancreatic Canceron April 9, 2021 at 1:51 pm
A recent review took a look at the promise of measuring circulating tumor DNA (ctDNA) with digital-droplet PCR (ddPCR) in pancreatic ductal adenocarcinoma (PDAC) as the landscape of this cancer ...
- AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Testson April 7, 2021 at 7:00 pm
AcornMed Biotechnology Co., Ltd. (AcornMed), a precision medicine organization that specializes in the testing and analysis of solid and blood tumors, announced today that they will incorporate ...
- Lurbinectedin Approval Ignites a Spark for Precision Medicine in Small Cell Lung Canceron April 7, 2021 at 7:05 am
Nisha A. Mohindra, MD, discusses the integration of lurbinectedin into the small cell lung cancer paradigm and remaining questions regarding future therapeutic directions.
via Bing News